Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Astellas Pharma Inc.
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Boehringer Ingelheim International GmbH
Cancer takes. Takes away time. Takes away loved ones. At Boehringer Ingelheim we are providing new hope for patients by taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immuno-oncology therapies and intelligent combination approaches to help combat many cancers.
Bristol Myers Squibb
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.
Exelixis is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new products for difficult-to-treat cancers. Discovery efforts have resulted in 4 approved products available worldwide. The cabozantinib clinical development program focuses on evaluation of potential activity in new tumor types as well as combinations with other agents through ISTs, CTEP collaboration, and pivotal studies, including the COSMIC and CONTACT clinical trial programs. Exelixis continues to invest in expansion of our product pipeline through internal drug discovery and strategic business development opportunities. The educational resources provided on this site may include information about a product or use that is not approved by the FDA.
Gilead Sciences Inc
Kite, a Gilead Company, is a global biopharmaceutical company. Kite’s singular focus is cell therapy to treat and potentially cure cancer. As the cell therapy leader, Kite has more approved CAR T indications to help more patients than any other company. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in 35 countries worldwide.
GSK is focused on maximising patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, tumour cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, antibody-drug conjugates and cell therapy, either alone or in combination. GSK is a science-led global healthcare company. For further information please visit:
Ipsen is a global biopharmaceutical company focused on transformative medicines in three key therapeutic areas - Oncology, Rare Diseases and Neuroscience. Among the top pharmaceutical companies in the world specializing in oncology, Ipsen seeks to address the challenges posed by the most difficult-to-treat cancers. Ipsen’s decades of work in oncology have generated differentiated treatments in indications with high unmet needs. Ipsen sells more than 20 medicines in over 110 countries, with a direct commercial presence in more than 35 countries. Ipsen's R&D is focused on its innovative technological platforms located Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.For information, visit:
Sysmex Asia Pacific Pte Ltd
In Asia Pacific, Sysmex is a market leader in the delivery of clinical IVD and health IT products and services for clinical laboratories, hospitals and healthcare organizations. Its products and solutions continuously help improve patient clinical services and efficiency advances resulting in cost savings, which in turn translate to the delivery of better patient care. Sysmex delivers total solutions in the field of haematology, haemostasis, urinalysis, clinical chemistry, immunoassay system, flow cytometry and life science. Supplying products and services to customers in more than 190 countries, Sysmex is one of the market leaders in haematology and coagulation instrumentation worldwide.
Veracyte, formerly HalioDx, is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. Our immuno-oncology diagnostic products and services are used to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies. Leveraging the pioneering work of Dr. Jérôme Galon, the company provides a unique range of immune scoring solutions, including the Immunoscore® assay for assessing the immune contexture of a tumor. Immunoscore® in colon cancer is available as a CLIA or CE marked test to guide day-to-day oncologists’ decisions. Immunoscore® can be a diagnostic platform for many cancers, as immune response to tumor is a key hallmark of disease progression.